LipoSeuticals closes Series A for novel drug delivery tech

LipoSeuticals said today that it closed a financing round for an undisclosed amount led by Hong Kong-based life sciences fund, Delos Capital.

The company has developed a sugar-lipid polymer-based formulation, Sulocence, which boosts drug stability and solubility. LipoSeuticals said it is applying the drug delivery technology to the reformulation of an array of marketed specialty drugs.

Get the full story at our sister site, Drug Delivery Business News.

The post LipoSeuticals closes Series A for novel drug delivery tech appeared first on MassDevice.

from MassDevice http://ift.tt/2tuxGgk